Enhanced efficacy and long-term survival with SBRT plus PD-1 inhibitors versus SBRT alone in unresectable HCC: a multicenter PSM study.

Oncologist · 2026 · PMC12923107 · PMID 41546382

Europe PMC DOI

hedged sentences

0.0530

closest p · 1.1× alpha

0.0660

boldest claim

The sentences

approached significanceP = .053so close (0.05 < p ≤ 0.1)

After matching, RT+PD-1 showed a higher objective response rate (ORR) that approached significance (48.4% vs 37.6%, P = .053).

also in 8,237 other papers

a favorable trendP = .066so close (0.05 < p ≤ 0.1)

Cox regression demonstrated a favorable trend for the combination therapy (HR = 0.74, 95% CI: 0.54-1.02, P = .066), although the difference did not reach statistical significance ( Figure 2 ).

also in 1,335 other papers

did not reach conventional levels of significanceno p-value reported

In other subgroups, including patients with prior treatment exposure or without distant metastasis, HRs generally favored RT+PD-1, although interaction tests were not statistically significant and subgroup-specific differences did not reach conventional levels of significance.

also in 76 other papers

showed a trendno p-value reported

Patients treated with RT+PD-1 showed a trend toward improved OS compared with those receiving RT alone.

also in 53,322 other papers

did not reach statistical significanceno p-value reported

The proportions of patients with more than 2 tumors (43.3% vs 40.2%, P = .177), PVTT (28.7% vs 26.3%, P = .289), and distant metastasis (27.4% vs 37.1%, P = .124) were numerically different but did not reach statistical significance.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.